Bio-Path Holdings, Inc. (BPTH)

$4.0229

+0.10 (+2.63%)
Rating:
Recommendation:
Buy
Symbol BPTH
Price $4.0229
Beta 1.745
Volume Avg. 0.07M
Market Cap 28.805M
Shares () -
52 Week Range 2.68-8.62
1y Target Est -
DCF Unlevered BPTH DCF ->
DCF Levered BPTH LDCF ->
ROE -42.49% Strong Sell
ROA -47.15% Strong Sell
Operating Margin -
Debt / Equity 7.90% Neutral
P/E -
P/B 1.29 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest BPTH news


Mr. Peter Nielsen
Healthcare
Biotechnology
NASDAQ Capital Market

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.